Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biomir is a biotechnology company specializing in regenerative medicine and tissue engineering, primarily known for its proprietary G-Derm technology. The company develops innovative collagen-based biomaterials that serve as a scaffold for cell growth, effectively mimicking the structure of human skin to accelerate healing. Biomir's product portfolio includes bioplastic films, sponges, and gels used in the treatment of severe burns, chronic wounds, and trophic ulcers, as well as in aesthetic medicine. Headquartered in Russia, the company has received significant recognition for its advancements in biomaterials and maintains a focus on expanding the clinical applications of its tissue-regenerating platform. Biomir's solutions are designed to provide a biocompatible environment that promotes natural tissue repair while reducing the risk of scarring.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biomir.